SEARCH

SEARCH BY CITATION

References

  • 1
    Solomon D, Davey D, Kurman R et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002;287:21149.
  • 2
    Herbert A, Bergeron C, Wiener H et al. European guidelines for quality assurance in cervical cancer screening: recommendations for cervical cytology terminology. Cytopathology 2007;18:2139.
  • 3
    Arbyn M, Herbert A, Schenck U et al. European guidelines for quality assurance in cervical cancer screening: recommendations for collecting samples for conventional and liquid-based cytology. Cytopathology 2007;18:1339.
  • 4
    Wright TC, Sun XW, Koulos J. Comparison of management algorithms for the evaluation of women with low-grade cytologic abnormalities. Obstet Gynecol 1995; 85:20210.
  • 5
    Arbyn M, Buntinx F, Van Ranst M et al. Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. J Natl Cancer Inst 2004; 96:28093.
  • 6
    Arbyn M, Dillner J, Van Ranst M et al. Re: Have we resolved how to triage equivocal cervical cytology? J Natl Cancer Inst 2004;96:14012.
  • 7
    Hinselmann H. Verbesserung der Inspektionsm”glichkeiten von Vulva, Vagina und Portio. Munch Med Wochenschr 1925;72:173342.
  • 8
    Jordan JA. Colposcopy in the diagnosis of cervical cancer and precancer. Clin Obstet Gynecol 1985;12:6776.
  • 9
    Sellors JW, Sankaranarayanan R. Colposcopy and Treatment of Cervical Intraepithelial Neoplasia: A Beginners’ Manual. Lyon: IARC; 2003:1132.
  • 10
    Walker P, Dexeus S, De Palo G et al. International terminology of colposcopy: an updated report from the International Federation for Cervical Pathology and Colposcopy. Obstet Gynecol 2003;101:1757.
  • 11
    Prendiville W, Ritter J, Tatti S, Twiggs L. Colposcopy: Management Options. Edinburgh: Saunders; 2003:1213.
  • 12
    Prendiville W. The treatment of grade 3 cervical intraepithelial neoplasia. In: Colposcopy: Management Options. PrendivilleW, RitterJ, TattiS, TwiggsLB (eds). Edinburgh: Saunders; 2003: pp. 12933.
  • 13
    Mor-Yosef S, Lopes A, Pearson S, Monaghan M. Loop diathermy cone biopsy. Obstet Gynecol 1990;73:8846.
  • 14
    Mitchell MF, Schottenfeld D, Tortolero-Luna G, Cantor SB, Richards Kortum R. Colposcopy for the diagnosis of squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol 1998;91:62631.
  • 15
    Pretorius RG, Belinson JL, Zhang WH et al. The colposcopic impression. Is it influenced by the colposcopist’s knowledge of the findings on the referral Papanicolaou smear?. J Reprod Med 2001;46:7248.
  • 16
    Pretorius RG, Zhang WH, Belinson JL et al. Colposcopically directed biopsy, random cervical biopsy, and endocervical curettage in the diagnosis of cervical intraepithelial neoplasia II or worse. Am J Obstet Gynecol 2004;191:4304.
  • 17
    NHSCSP. Standards and quality in colposcopy. In: NHS Cancer Screening Programmes, Vol. 2. LuesleyD (ed.). Sheffield: NHSCSP Publications; 1996: pp. 127.
  • 18
    NHSCSP. The Colposcopy Examination. London: Cancer Research UK; 1996.
  • 19
    NHSCSP. Guidance notes on the safe use of diathermy loop excision for the treatment of cervical intraepithelial neoplasia. In: NHS Cancer Screening Programmes, Vol. 4. HancockCW (ed.). NHSCSP, Sheffield: NHSCSP Publications; 1997: pp. 110.
  • 20
    NHSCSP. Colposcopy and programme management: guidelines for the NHS Cervical Screening Programme. In: NHS Cancer Screening Programmes, Vol. 20. LuesleyD, LeesonS (eds). Sheffield, Manor House: NHSCSP publication; 2004: pp. 180.
  • 21
    Martin M, Prendiville W. Is local anaesthetic infiltration less painful than cervical punch biopsy. A study comparing the amount of pain felt by women attending a colposcopy clinic who required a cervical punch biopsy. In: Annual Meeting. British Society of Colposcopy and Cervical Pathology (ed.). Edinburgh: BSCCP; 2004.
  • 22
    Abdel-Hady ES, Martin-Hirsch P, Duggan-Keen M et al. Immunological and viral factors associated with the response of vulval intraepithelial neoplasia to photodynamic therapy. Cancer Res 2001;61:1926.
  • 23
    Cartier R, Cartier I. Practical Colposcopy, 3rd edn. Paris: Laboratoire Cartier; 1993.
  • 24
    Prendiville W, Davies R, Berry PJ. A low voltage diathermy loop for taking cervical biopsies. A qualitative comparison with punch biopsy forceps. Br J Obstet Gynaecol 1986;93:7736.
  • 25
    Anderson MC, Jordan JA, Morse AR, Sharpe F. Integrated Colposcopy, 2nd edn. London: Chapman and Hall; 1996.
  • 26
    Ismail SM, Colclough AB, Dinnen JS et al. Observer variation in histopathological diagnosis and grading of cervical intraepithelial neoplasia. BMJ 1989;298:70710.
  • 27
    Stoler MH, Schiffman MA. Interobserver reproducibility of cervical cytologic and histologic interpretations. JAMA 2001;285:15005.
  • 28
    Horvat R, Jordan J, Herbert A, Wiener H. Chapter 5: Techniques and quality assurance guidelines for histopathology. In: European Guidelines for Quality Assurance in Cervical Cancer Screening. ArbynM, AnttilaA, JordanJ et al. (eds). Luxembourg: Office for Official Publications of the European Communities; 2008: pp. 17389.
  • 29
    Weitzman GA, Korhonen MO, Reeves KO et al. Endocervical brush cytology. An alternative to endocervical curettage?. J Reprod Med 1988;33:67783.
  • 30
    Andersen W, Frierson H, Barber S et al. Sensitivity and specificity of endocervical curettage and the endocervical brush for the evaluation of the endocervical canal. Am J Obstet Gynecol 1988;159:7027.
  • 31
    Hoffman MS, Sterghos S Jr, Gordy LW, Gunasekar D. Evaluation of the cervical canal with the endocervical brush. Obstet Gynecol 1993;82:5737.
  • 32
    Mogensen ST, Bak M, Dueholm M et al. Cytobrush and endocervical curettage in the diagnosis of dysplasia and malignancy of the uterine cervix. Acta Obstet Gynecol Scand 1997;76:6973.
  • 33
    Gath DH, Hallam N, Mynors-Wallis L, Day A, Bond SAK. Emotional reactions in women attending a UK colposcopic clinic. J Epidemiol Community Health 1995; 49:7983.
  • 34
    Wright TC, Cox JT, Massad LS, Wilkinson EJ. 2001 Consensus guidelines for the management of women with cervical cytological abnormalities. JAMA 2002; 287:21209.
  • 35
    Anttila A, Ronco G, Lynge E et al. Chapter 2: Epidemiological guidelines for quality assurance in cervical cancer screening. In: European Guidelines for Quality Assurance in Cervical Cancer Screening. ArbynM, AnttilaA, JordanJ et al. (eds). Luxembourg: Office for Official Publications of the European Communities; 2008: pp. 1152.
  • 36
    Arbyn M, Dillner J, Schenck U et al. Chapter 3: Methods for screening and diagnosis. In: European Guidelines for Quality Assurance in Cervical Cancer Screening. ArbynM, AnttilaA, JordanJ et al. (eds). Luxembourg: Office for Official Publications of the European Communities; 2008: pp. 69152.
  • 37
    Melnikow J, Nuovo J, Willan AR, Chan BK, Howell LP. Natural history of cervical squamous intraepithelial lesions : a meta-analysis. Obstet Gynecol 1998;92:72735.
  • 38
    Nygard JF, Skare GB, Thoresen SO. The cervical cancer screening programme in Norway, 1992–2000: changes in Pap smear coverage and incidence of cervical cancer. J Med Screen 2002;9:8691.
  • 39
    ASCUS-LSIL Triage Study Group. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 2003;188:138392.
  • 40
    Morin C, Bariati C, Bouchard C et al. Managing atypical squamous cells of undetermined significance in Papanicolaou smears. J Reprod Med 2001;46:799805.
  • 41
    Solomon D, Schiffman MA, Tarone B. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance (ASCUS): baseline results from a randomized trial. J Natl Cancer Inst 2001;93:2939.
  • 42
    Arbyn M, Sasieni P, Meijer CJ et al. Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses. Vaccine 2006;24(Suppl. 3):7889.
  • 43
    Cox JT, Schiffman MA, Solomon D. Prospective follow-up suggests similar risk of subsequent cervical intraepithelial neoplasia grade 2 or 3 among women with cervical intraepithelial neoplasia grade 1 or negative colposcopy and directed biopsy. Am J Obstet Gynecol 2003;188:140612.
  • 44
    Guido R, Schiffman MA, Solomon D, Burke L. Postcolposcopy management strategies for women referred with low-grade squamous intraepithelial lesions or human papillomavirus DNA-positive atypical squamous cells of undetermined significance: a two-year prospective study. Am J Obstet Gynecol 2003;188:14015.
  • 45
    Cuzick J, Szarewski A, Cubie H et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet 2003; 362:18716.
  • 46
    Coleman D, Day N, Douglas G et al. European guidelines for quality assurance in cervical cancer screening. Europe against cancer programme. Eur J Cancer 1993; 29A(Suppl. 4):S138.
  • 47
    Sawaya GF. A 21-year-old woman with atypical squamous cells of undetermined significance. JAMA 2005;294:22108.
  • 48
    Holowaty P, Miller AB, Rohan T, To T. Natural history of dysplasia of the uterine cervix. J Natl Cancer Inst 1999;91:2528.
  • 49
    Arbyn M, Paraskevaidis E, Martin-Hirsch P, Prendiville W, Dillner J. Clinical utility of HPV DNA detection: triage of minor cervical lesions, follow-up of women treated for high-grade CIN. An update of pooled evidence. Gynecol Oncol 2005;99(Suppl. 3):711.
  • 50
    Bergeron C, Jeannel D, Poveda J, Cassonnet P, Orth G. Human papillomavirus testing in women with mild cytologic atypia. Obstet Gynecol 2000;95:8217.
  • 51
    Ferris DG, Wright TC Jr, Litaker MS et al. Comparison of two tests for detecting carcinogenic HPV in women with Papanicolaou smear reports of ASCUS and LSIL. J Fam Pract 1998;46:13641.
  • 52
    Nobbenhuis MAE, Walboomers JM, Helmerhorst TJM et al. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet 1999; 354:205.
  • 53
    Nobbenhuis MA, Helmerhorst TJ, Van Den Brule AJ et al. Cytological regression and clearance of high-risk human papillomavirus in women with an abnormal cervical smear. Lancet 2001;358:17823.
  • 54
    Remmink AJ, Walboomers JM, Helmerhorst TJM et al. The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: natural history up to 36 months. Int J Cancer 1995;61:30611.
  • 55
    Van Duin M, Snijders PJ, Schrijnemakers HF et al. Human papillomavirus 16 load in normal and abnormal cervical scrapes: an indicator of CIN II/III and viral clearance. Int J Cancer 2002;98:5905.
  • 56
    Schlecht NF, Platt RW, Duarte-Franco E et al. Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia. J Natl Cancer Inst 2003;95:133643.
  • 57
    ASCUS-LSIL Triage Study Group. A randomized trial on the management of low-grade squamous intraepithelial lesion cytology interpretations. Am J Obstet Gynecol 2003;188:1393400.
  • 58
    Kurman RJ, Henson DE, Herbst AL et al. Interim guidelines for management of abnormal cervical cytology. JAMA 1994;271:18669.
  • 59
    Taylor RR, Guerrieri JP, Nash JD, Henry MR, O’Connor DM. Atypical cervical cytology. Colposcopic follow-up using the Bethesda System. J Reprod Med 1993; 38:4437.
  • 60
    Duska LR, Flynn CF, Chen A, Whall-Strojwas D, Goodman A. Clinical evaluation of atypical glandular cells of undetermined significance on cervical cytology. Obstet Gynecol 1998;91:27882.
  • 61
    Kennedy AW, Salmieri SS, Wirth SL et al. Results of the clinical evaluation of atypical glandular cells of undetermined significance (AGCUS) detected on cervical cytology screening. Gynecol Oncol 1996;63:148.
  • 62
    Ronnett BM, Manos M, Ransley JE et al. Atypical glandular cells of undetermined significance (AGUS): cytopathologic features, histopathologic results, and human papillomavirus DNA detection. Hum Pathol 1999;30:81625.
  • 63
    Eddy GL, Strumpf KB, Wojtowycz MA, Piraino PS, Mazur MT. Biopsy findings in five hundred thirty-one patients with atypical glandular cells of uncertain significance as defined by the Bethesda system. Am J Obstet Gynecol 1997;177:118895.
  • 64
    Soofer SB, Sidawy MK. Atypical glandular cells of undetermined significance: clinically significant lesions and means of patient follow-up. Cancer 2000;90:20714.
  • 65
    Valdini A, Vaccaro C, Pechinsky G, Abernathy V. Incidence and evaluation of an AGUS Papanicolaou smear in primary care. J Am Board Fam Pract 2001;14:1727.
  • 66
    Kim TJ, Kim HS, Park CT et al. Clinical evaluation of follow-up methods and results of atypical glandular cells of undetermined significance (AGUS) detected on cervicovaginal Pap smears. Gynecol Oncol 1999;73:2928.